Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Background: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tolerability profile, but no studies have demonstrate...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancers (Basel)
Main Authors: Vernieri, Claudio, Prisciandaro, Michele, Nichetti, Federico, Lobefaro, Riccardo, Peverelli, Giorgia, Ligorio, Francesca, Zattarin, Emma, Cona, Maria Silvia, Sepe, Pierangela, Corti, Francesca, Manglaviti, Sara, Brambilla, Marta, Re, Barbara, Belfiore, Antonino, Pruneri, Giancarlo, Celio, Luigi, Mariani, Gabriella, Bianchi, Giulia Valeria, Rivoltini, Licia, Capri, Giuseppe, de Braud, Filippo
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139362/
https://ncbi.nlm.nih.gov/pubmed/32155941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030617
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים